MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of common stock...
$24,847K
Issuance of common stock
through employee stock...
$649K
Proceeds from the
exercise of stock options
$242K
Proceeds from maturities
of investment...
$314,885K
Net cash provided by
financing activities
$25,738K
Net cash provided by
investing activities
$22,913K
Canceled cashflow
$291,972K
Net decrease in cash
and cash...
-$5,707K
Canceled cashflow
$48,651K
Stock-based compensation
$14,549K
Accounts payable and
other liabilities
$4,486K
Depreciation
$622K
Deferred financing costs
$427K
Purchases of investment
securities
$291,779K
Purchases of property and
equipment
$193K
Net cash used in
operating activities
-$54,358K
Canceled cashflow
$20,084K
Net loss
-$69,792K
Amortization of premiums on
investment securities, net
$3,253K
Prepaid expense and
other assets
$1,376K
Non-cash lease expense
-$21K
Back
Back
Cash Flow
source: myfinsight.com
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)